Olmetec Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmetec Plus, is an angiotensin II receptor blocker combined with a thiazide diuretic presented as a tablet for oral use. It treats hypertension and is indicated for adults who require blood pressure control.

GNH USA supplies Olmetec Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmetec Plus is an antihypertensive agent that works within the renin‑angiotensin‑aldosterone system to lower blood pressure. - Essential hypertension: helps achieve target blood pressure levels in patients with primary high blood pressure. - Hypertension with volume overload: provides additional diuretic effect to reduce fluid retention. - Hypertension in diabetic patients: assists in blood pressure control while offering renal protective benefits.

Olmetec Plus may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Liver enzyme elevation - Blood dyscrasias such as agranulocytosis

When prescribing Olmetec Plus, clinicians should consider several safety aspects. - Renal function monitoring: assess serum creatinine and eGFR before and during therapy. - Electrolyte balance: check potassium and sodium levels regularly. - Pregnancy: avoid use, especially in the second and third trimesters. - Concomitant NSAIDs: monitor for reduced antihypertensive effect and renal impairment. - Gout history: use cautiously as thiazides may increase uric acid. Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Olmetec Plus can interact with several drug classes, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Aliskiren: combined use may cause excessive hypotension and renal dysfunction. - Lithium: risk of lithium toxicity due to reduced renal clearance. - Potassium‑saving diuretics or supplements: may precipitate hyper‑kalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response and affect renal function. - ACE inhibitors or other ARBs: additive blood‑pressure lowering effect, risk of hyper‑kalemia. - Antidiabetic agents: may enhance hypoglycaemic effect, requiring dose adjustment.